Nabriva Therapeutics AG (NBRV) Given Media Impact Score of 0.12
News articles about Nabriva Therapeutics AG (NASDAQ:NBRV) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nabriva Therapeutics AG earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.370340987168 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded down $0.08 on Tuesday, hitting $5.77. The stock had a trading volume of 824,700 shares, compared to its average volume of 265,511. Nabriva Therapeutics AG has a 1 year low of $3.52 and a 1 year high of $14.10.
Several analysts have weighed in on NBRV shares. Zacks Investment Research upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating and set a $12.00 price target on the stock in a research note on Tuesday, July 18th. ValuEngine downgraded Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. SunTrust Banks, Inc. started coverage on Nabriva Therapeutics AG in a research note on Friday, August 25th. They set a “buy” rating and a $20.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research note on Monday, August 28th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Nabriva Therapeutics AG presently has a consensus rating of “Buy” and a consensus target price of $19.03.
TRADEMARK VIOLATION NOTICE: “Nabriva Therapeutics AG (NBRV) Given Media Impact Score of 0.12” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/14/nabriva-therapeutics-ag-nbrv-given-media-impact-score-of-0-12.html.
In related news, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of the stock in a transaction dated Monday, September 18th. The shares were purchased at an average price of $9.46 per share, for a total transaction of $497,889.26. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 36,608 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $8.56, for a total value of $313,364.48. The disclosure for this sale can be found here. Insiders bought 57,219 shares of company stock worth $535,919 in the last 90 days. Company insiders own 2.75% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.